The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals
The registry record from ClinicalTrials.gov (public domain): summary, interventions, outcomes and eligibility. Questions are answered only with quotes from this document. Source: ClinicalTrials.gov, retrieved 2026-11-05.
Ongoing
Record metadata
- Phase
- NA
- Status
- Enrolling by invitation
- Start
- 2022-09-01
- End
- 2042-12-31
- Enrollment
- 200
- Sites
- 1
- Sponsor class
- OTHER
Not in the data yet: a trial card. A one-glance card (population, design, endpoints, result, each tied to a quote) is not built yet. The fields above are registry or bibliographic metadata, not quotes.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you get that instead of a guess.
Source text
Brief summary · public domain (ClinicalTrials.gov) · T1
The objective of this national and multidisciplinary project is to establish and evaluate a personalized surveillance program (SP) for early diagnosis of pancreatic cancer (PC) and its precursors in individuals with a hereditary predisposition to the disease (High RIsk Individuals (HRI)). Patients who either carry a germline mutation in a PC susceptibility gene (CDKN2A, STK11, TP53, PRSS1), or have a strong family history of PC, will be enrolled through their genetics clinic at the university hospitals in Oslo, Bergen, Trondheim and Tromsø. Surveillance consists of annual MRI, assessment of blood glucose and lipid levels, new onset diabetes (NOD) and unintentional weight loss. Blood samples will be drawn for ctDNA-analysis (circulating tumor DNA) and the IMMrayTM PanCan-d test (a novel microarray-based diagnostic test for PC) at baseline and in those who develop lesions. The psychological burden and cost-benefit of the SP will be analyzed. The study addresses an unmet need for the care of HRI in Norway, and is expected to improve PC prognosis. It will be the first to provide evidence on the combined value of a panel of blood-borne biomarkers in surveillance, and provide morphological and molecular data on PC and (non)-neoplastic pancreatic changes in HRI.
Intervention · public domain (ClinicalTrials.gov) · T1
Other: Annual surveillance. Annual surveillance includes annual MRI and/or an assessment new onset diabetes and unintended weight loss.
Primary outcome · public domain (ClinicalTrials.gov) · T1
Prognosis of pancreatic cancer in patients diagnosed through the surveillance programme compared to prognosis in unscreened individuals as reported to the Cancer Registry of Norway.. We will investigate whether 3 year, 5 year and long term survival in HRIs undergoing surveillance is improved compared to rates of survival of pancreatic cancer in the general unscreened population. Survival data for the general population will be collected from the Cancer Registry of Norway. Data on prognosis of pancreatic cancer in patients undergoing surveillance will be collected from electronic patient records, The Cancer Registry of Norway and the National Population Register. Time frame: Up to 20 years.
Primary outcome · public domain (ClinicalTrials.gov) · T1
Number of resectable cancers detected in patients diagnosed through the surveillance programme compared to the unscreened individuals as reported to the Cancer Registry of Norway.. We will investigate whether the number of surgically resectable cancers is higher in HRIs undergoing screening through the surveillance programme compared to pancreatic cancer diagnosed in the general population of Norway. Data on number of resectable cancers in the general Norwegian population will be collected from the Cancer Registry of Norway. Data on cancers diagnosed in the HRI will be collected from electronic patient records and The Cancer Registry of Norway. Time frame: 20 years.
Secondary outcome · public domain (ClinicalTrials.gov) · T1
Healthcare utilization. Time frame: 20 years.
Secondary outcome · public domain (ClinicalTrials.gov) · T1
Quality of life of participants undergoing surveillance as assessed with the Hospital Anxiety and Depression Scale (HADS). Time frame: 10 years.
Secondary outcome · public domain (ClinicalTrials.gov) · T1
Costs. Time frame: Up to 20 years.
Secondary outcome · public domain (ClinicalTrials.gov) · T1
Cost-effectiveness analysis. Time frame: Up to 20 years.
Secondary outcome · public domain (ClinicalTrials.gov) · T1
Quality of life of participants undergoing surveillance as assessed with the Impact of Event Scale (IES). Time frame: 10 years.
Secondary outcome · public domain (ClinicalTrials.gov) · T1
The cancer worry of participants undergoing surveillance as assessed with the Cancer Worry Scale. Time frame: 10 years.
Eligibility · public domain (ClinicalTrials.gov) · T1
Inclusion Criteria: 1. Men or women with a germline mutation in CDKN2A, TP53, PRSS1 or STK11 2. Men or women who are first degree relatives to a patient with pancreatic cancer (PC) in a family with Familial Pancreatic Cancer (FPC). Exclusion Criteria: Patients undergoing active cancer treatment.
Enrollment · public domain (ClinicalTrials.gov) · T1
Enrollment: 200 participants (estimated).